Skip to content

EBIT at other companies

Eli Lilly logo
Eli LillyLLY
Medtronic logo
MedtronicMDT
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
Abbott logo
AbbottABT
Viatris logo
ViatrisVTRS

Other financials

Income statement

See full
Revenue$761.7M+33.9%
Gross profit$529.0M+29.3%
Operating income$122.1M+37.5%
Net income$91.1M+157%
EPS (diluted)$1.30+160%

Balance sheet

See full
Cash & equivalents$480.4M-62.6%
Total debt$969.7M-45.5%
Total equity$1.3B-2.1%
Total assets$3.0B-15.1%

Cash flow

See full
Operating cash flow$113.8M+78.4%
CapEx$24.3M+97.6%
Free cash flow$89.5M+73.8%

Valuation

See full
Market cap$10.1B-19.9%
Enterprise value$10.59B-19.4%
P/E33.3×+2.0×
P/S3.5×-2.3×

Profitability

See full
Gross margin71%+0.6pp
Operating margin17.5%+2.0pp
Net margin10.4%-7.9pp
FCF margin14.3%+1.1pp

Returns & leverage

See full
Return on equity23%-14.9pp
Debt / equity0.7×-0.6×
Current ratio2.5×-2.0×

Where this comes from

Calculated from Insulet’s reported figures.

The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insulet's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insulet's EBIT?
Insulet (PODD) reported EBIT of $122.1M in Q1 2026.
How has Insulet's EBIT changed year-over-year?
Insulet's EBIT increased by 37.5% year-over-year, from $88.8M to $122.1M.
What is the long-term trend for Insulet's EBIT?
Over 4 years (2021 to 2025), Insulet's EBIT has grown at a 39.3% compound annual growth rate (CAGR), from $126M to $473.9M.
What does EBIT mean?
Profit before interest and taxes — the business's core earning power.
How do you interpret EBIT?
Higher is better. Because it adds back interest, EBIT compares earning power across firms with very different debt loads — the base for interest coverage and the EV/EBIT multiple. For filers reporting operating income it equals that line, excluding non-operating swings.
How does EBIT compare across companies?
Comparable across companies regardless of leverage or tax domicile; the standard 'earning power' line for cross-company analysis. Least meaningful for banks and insurers.